Clinical Trial Update: Proof of Concept Study Evaluating RNS60 in the Treatment of Relapsing Remitting Multiple Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 proof-of-concept trial evaluating RNS60 for Relapsing-Remitting Multiple Sclerosis has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Relapsing-remitting Multiple Sclerosis

Drugs mentioned

• RNS60

Snippet

Sponsor: Revalesio Corporation | Conditions: Relapsing Remitting Multiple Sclerosis | Phase 2 | Status: WITHDRAWN